Diasorin SpA
DIA
Company Profile
Business description
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment’s importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
Contact
Via Crescentino Snc
Saluggia
Vercelli13040
ITAT: +39 161487526
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
3,281
Stocks News & Analysis
stocks
Cheap retail REIT with an attractive yield
Lower consumer spending unlikely to buckle this retail REIT.
stocks
Expanding store network for ASX listed retailer
Sales growth but lack of margin expansion due to competition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,131.30 | 71.80 | 0.79% |
| CAC 40 | 8,447.27 | 63.26 | 0.75% |
| DAX 40 | 24,910.41 | 16.40 | 0.07% |
| Dow JONES (US) | 51,999.67 | 328.64 | 0.64% |
| FTSE 100 | 10,494.21 | 63.59 | 0.61% |
| HKSE | 24,493.95 | 348.72 | -1.40% |
| NASDAQ | 26,376.34 | 307.60 | -1.15% |
| Nikkei 225 | 69,404.50 | 87.00 | 0.13% |
| NZX 50 Index | 13,395.12 | 31.01 | -0.23% |
| S&P 500 | 7,511.35 | 42.94 | -0.57% |
| S&P/ASX 200 | 8,917.70 | 77.30 | 0.87% |
| SSE Composite Index | 4,091.89 | 4.58 | -0.11% |